Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma

Brief Title

Studying Protein Expression in Tissue Samples From Younger Patients With Rhabdomyosarcoma

Official Title

Tissue Microarray Studies of the 12q13-q14 Amplicon in Alveolar Rhabdomyosarcoma

Brief Summary

      This research trial studies protein expression in tissue samples from younger patients with
      rhabdomyosarcoma. Studying samples of tissue from patients with cancer in the laboratory may
      help doctors learn more about changes that occur in DNA and identify biomarkers related to
      cancer. It may also help doctors find better ways to treat cancer.
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To investigate (in two stages) which proteins are overexpressed in association with
      12q13-q14 amplification by applying fluorescence in situ hybridization (FISH) and
      immunohistochemical (IHC) assays to a panel of alveolar rhabdomyosarcomas (ARMS) cases
      organized into tissue microarrays.

      OUTLINE:

      Formalin-fixed paraffin-embedded tissue samples are analyzed for 12q13-q14 frequency and
      protein overexpression by FISH and IHC.
    


Study Type

Observational


Primary Outcome

Amplification and fusion status as a result of the 12q13-q14 amplification event


Condition

Alveolar Childhood Rhabdomyosarcoma

Intervention

laboratory biomarker analysis

Study Arms / Comparison Groups

 Correlative studies
Description:  Formalin-fixed paraffin-embedded tissue samples are analyzed for 12q13-q14 frequency and protein overexpression by FISH and IHC.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

99

Start Date

June 2012

Completion Date

May 2016

Primary Completion Date

May 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Slides of the 2006 alveolar rhabdomyosarcoma (ARMS) TMA and the 2009 ARMS/anaplastic
             embryonal rhabdomyosarcoma (ERMS) TMA

               -  PAX3-FOXO1-positive tumors

               -  PAX7-FOXO1-positive tumors

               -  Fusion-negative tumors
      

Gender

All

Ages

N/A - 21 Years

Accepts Healthy Volunteers

No

Contacts

Frederick Barr, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01609803

Organization ID

ARST12B7

Secondary IDs

NCI-2012-01972

Responsible Party

Sponsor

Study Sponsor

Children's Oncology Group

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Frederick Barr, MD, Principal Investigator, Children's Oncology Group


Verification Date

May 2016